Abstract: The soft toric contact lens has a substantially rotationally symmetrical front face optionally having a rotationally symmetrical lenticular construction, and a substantially aspherical, especially ellipsoidal, rear face. The optically active central region of the rear face is toric. Shifting the torus to the central region of the lens rear face results in lenses that are economic to produce, are of wearable thickness and are straightforward to fit.

Abstract: In order to remove impurities and contaminations adhering to the surfaces of an optical component, especially to the front and rear faces of a contact lens, electromagnetic radiation is caused to act on the optical component. Using that electromagnetic radiation, preferably the light of an excimer laser the wavelength, energy density and intensity of which are adjustable, the adherent impurities and any microorganisms present are killed, deactivated and removed photo-ablatively.

Abstract: A contact lens casting mould includes two casting mould halves. A concave shaping surface (11) is constructed on a female part (1) and a convex shaping surface (21) on a male part (2). When joined together, the two casting mould halves (1 and 2) adhere by frictional connection.

Abstract: In the process described, a limited number of shaping tools (T.sub.1, T.sub.2, . . . , T.sub.N) having standardized parameters (for the production of the following contact lens parameters: contact lens diameter, radius of curvature of the rear face of the contact lens, vertex refraction) is used for the manufacture of standardized moulds (M.sub.1, M.sub.2, . . . , M.sub.N). Preferably by material-removing machining of the moulds, moulds are produced that have additional altered parameters. The multiplicity of moulds produced in that manner is used for the one-step manufacture (F) of contact lenses (L) having different parameters that largely do not have to be finished.

Abstract: A contact lens that consists of gas-permeable, especially oxygen-permeable, lens material and has a supporting edge which rests on the sclera and is covered at least partially by both eyelids and absorbs the forces acting on the lens as the lid closes, the rear face of the lens in the region of the cornea being spaced from the surface of the cornea. By ensuring the exchange of lachrymal fluid between the contact lens and the surface of the eye, metabolic products are transported away and the supply of oxygen to the cornea is assisted. For that purpose, channels may be provided on the lens or the lens may be caused to rotate.

Abstract: A method for the manufacture of contact lenses, especially individually fitted contact lenses, and a contact lens production system therefor is described, wherein the topography of the surface of the eye is measured three-dimensionally, the geometry of the rear face of the lens is determined so as to fit the topography measured, the optical effect of a lachrymal lens which is formed between the rear face of the lens and the surface of the eye is determined, the geometry of the front face of the lens is determined taking into account the optical effect of the lachrymal lens and the sight correction to be achieved, and the data so obtained for the lens geometry of the front and rear faces of the lens are stored and transferred to a control arrangement for the manufacture of the lens in a machine tool.

Abstract: A contact lens has an elliptical inside surface with a numerical eccentricity of 0.2 to 0.5 and a zenith radius of curvature of 8.0 to 8.4 mm. The inside surface preferably has a peripheral, circularly cross sectioned bevelled zone. As a soft contact lens, it has these dimensions when fully hydrated and preferably consists of a copolymer comprising of 50% to 90% hydroxyethyl-methacrylate (HEMA) by weight, 2% to 20% one or more unsaturated carboxylic acids, 2% to 20% one or more base monomers, 5% to 25% aliphatic acrylate or methacrylate, and 0.1% to 1% of a dialkylene-glycol-dimethacrylate cross-linker.

Abstract: Apparatus for singularizing successive stacks of a series of stacks consisting of superimposed groups of sheets has a transporting unit which advances successive stacks of the series in a horizontal plane against a barrier which intercepts each but the lowermost group of the oncoming stack. An endless conveyor with one or more pushers is provided to advance successive lowermost groups of an intercepted stack through and beyond a clearance between the barrier and a stationary table of the transporting unit. The width of such clearance exceeds the height of a single group but is less than the combined height of two superimposed groups. The width of the clearance and the extent to which the pusher or pushers can extend above the horizontal plane are adjustable.

Abstract: A 6-thioxanthine of formula I or a pharmaceutically acceptable salt thereof ##STR1## wherein R.sub.3 is a C.sub.2 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group and R.sub.8 is a C.sub.1 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group provided that when R.sub.3 is an ethyl, n-propyl or n-butyl group, R.sub.8 is a C.sub.3 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group.These 3,8-disubstituted-6-thioxanthines have enhanced bronchodilator activity.

Abstract: A 6-thioxanthine of general formula I or a pharmaceutically acceptable salt thereof ##STR1## wherein R.sub.3 is a C.sub.2 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group and R.sub.8 is a C.sub.1 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group provided that when R.sub.3 is an ethyl, n-propyl or n-butyl group, R.sub.8 is a C.sub.3 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group.These 3,8-disubstituted-6-thioxanthines have enhanced bronchodilator activity.

Abstract: Antihypertension action is achieved without diuresis by administration of a thiazide diuretic in an amount which while being sufficient to achieve antihypertension is insufficient to achieve diuresis. Such administration in a non-diuretic amount is effected in 4-8 consecutive hourly doses to achieve reduction of blood pressure without high urine output. The invention further relates to complexes of thiazides with mixed cation-anion exchange resins, to insoluble basic metal hydroxy thiazide salts, the salts of thiazide with calcium disodium edetate or disodium edetate, to molecular complexes of thiazides with long chain polymers such as hydroxy alkyl cellulose polymers, carboxy methyl cellulose and polyvinylpyrrolidone, to beta-adrenergic blocking amine-thiazide salts and to amiloride thiazide salts.

Abstract: Compounds of the formula ##STR1## wherein R.sup.3 is ethyl, n-propyl or n-butyl, andR.sup.8 is hydrogen, methyl or ethyl,exhibit bronchodilating activity with reduced side effects and increased half-like. A method of achieving bronchodilation with reduced undesired effects (diuresis, CNS activity), by administering the said compounds to a patient, is also provided.

Abstract: A multifocal, especially bifocal, intraocular, artificial ophthalmic lens of transparent material, whose optical lens portion is divided into near range and far range zones and, each of which is disposed on the optical lens portion with approximately equal surface proportions and symmetrically with the lens axis.

Abstract: Analgesic and anti-inflamatory compounds of the formula ##STR1## wherein n=0-1,X=Halo, lower Alkoxy, HO--, Lower Alkyl, andR= ##STR2##

Abstract: New iodophor compositions are provided which are mixtures of polydextrose-iodine and polyvinylpyrrolidone-iodine. Such mixtures containing polydextrose-iodine and polyvinylpyrrolidone-iodine, wherein the ratio by weight of polydextrose to polyvinylpyrrolidone is between 20-80: 80-20, have an immediate bactericidal activity upon application and also a long lasting microbicidal activity. The immediate microbicidal acitivity is faster and more effective than by the use of either the polydextrose-iodine alone or the polyvinylpyrrolidone-iodine alone, and the effect is more long lasting than in the case of the use of either polydextrose-iodine alone or polyvinylpyrrolidone-iodine alone.

Abstract: Compounds of the formula ##STR1## wherein R.sup.3 is ethyl, n-propyl or n-butyl, andR.sup.8 is hydrogen, methyl or ethyl,exhibit bronchodilating activity with reduced side effects and increased half-life. A method of achieving bronchodilation with reduced undesired effects (diuresis, CNS activity), by administering the said compounds to a patient, is also provided.

Abstract: An armour plate (1) comprises cavities (2), which are arranged with a plurality of packing bodies (3) in an irregular or regular shape relative to each other. The packing bodies are hollow-bodied, preferably spherical or tubular, and consist of a non-metallic material, preferably glass or ceramic. The interspaces between the packing bodies are filled out with a plastics, preferably a foam made for example of polyurethane.

Abstract: Analgesic and anti-inflammatory compounds are provided. These compounds possess the following general formula: ##STR1## wherein R=--COOR.sub.5, --CH.sub.2 CO.sub.2 H, ##STR2## wherein A and B=hydrogen, lower alkyl, hydroxy alkyl, lower alkyl amine, substituted lower alkyl amine, aminoalkyl, substituted aminoalkyl;R.sub.5 =lower alkyl;R.sub.1 =aryl, substituted aryl, aralkyl, alkyl, hydrogen, substituted aralkyl and heterocycle;R.sub.2 =aryl, substituted aryl, aralkyl, alkyl, substituted aralkyl, heterocycle, substituted heterocycle, biphenyl, substituted biphenyl, naphthyl, and substituted naphthyl;R.sub.3 =aryl, substituted aryl, hydrogen, aralkyl, substituted aralkyl, alkyl, heterocycle and substituted heterocycle;R.sub.2 and R.sub.3 together form a ring;R.sub.4 =hydrogen, phenyl, substituted phenyl, heterocycle; alkyl, substituted alkyl; or, R.sub.1 and R.sub.4 may form a ring; ##STR3## --CH.sub.2 --; Y=--S--CHR.sub.4 --, --O--OHR.sub.4 --,--CHR.sub.4 --, --CR.sub.6 R.sub.7 --CHR.sub.4, ##STR4## wherein R.

Abstract: Analgesic and anti-inflammatory compounds are provided. These compounds possess the following general formula: ##STR1## wherein R=--COOR.sub.5, --CH.sub.2 CO.sub.2 H, ##STR2## wherein A and B=hydrogen, lower alkyl, hydroxy alkyl, lower alkyl amine, substituted lower alkyl amine, aminoalkyl, substituted aminoalkyl;R.sub.5 =lower alkyl;R.sub.1 =aryl, substituted aryl, aralkyl, alkyl, hydrogen, substituted aralkyl and heterocycle;R.sub.2 =aryl, substituted aryl, aralkyl, alkyl, substituted aralkyl, heterocycle, substituted heterocycle, biphenyl, substituted biphenyl, naphthyl, and substituted naphthyl;R.sub.3 =aryl, substituted aryl, hydrogen, aralkyl, substituted aralkyl, alkyl, heterocycle and substituted heterocycle;R.sub.2 and R.sub.3 together form a ring;R.sub.4 =hydrogen, phenyl, substituted phenyl, heterocycle; alkyl, substituted alkyl; or, R.sub.1 and R.sub.4 may form a ring;X=>C.dbd.O, --CH.sub.2 --;Y=--S--CHR.sub.4 --, --O--OHR.sub.4 --, --CHR.sub.4 --, --CR.sub.6 R.sub.7 --CHR.sub.

Abstract: A multifocal, especially bifocal, intraocular, artificial ophthalmic lens of transparent material, whose optical lens portion is divided into near range and far range zones and, each of which is disposed on the optical lens portion with approximately equal surface proportions and symmetrically with the lens axis.